312 related articles for article (PubMed ID: 33578709)
1. Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure.
Velikova T; Krastev B; Lozenov S; Gencheva R; Peshevska-Sekulovska M; Nikolaev G; Peruhova M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33578709
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
[TBL] [Abstract][Full Text] [Related]
3. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
4. Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer.
Hou X; Zheng Z; Wei J; Zhao L
Front Immunol; 2022; 13():1030745. PubMed ID: 36426359
[TBL] [Abstract][Full Text] [Related]
5. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
6. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
[TBL] [Abstract][Full Text] [Related]
7. The role of the gut microbiota in tumor, immunity, and immunotherapy.
Xie Y; Liu F
Front Immunol; 2024; 15():1410928. PubMed ID: 38903520
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome as a treatment in colorectal cancer.
Khan M; Shah S; Shah W; Khan I; Ali H; Ali I; Ullah R; Wang X; Mehmood A; Wang Y
Int Rev Immunol; 2024; 43(4):229-247. PubMed ID: 38343353
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
10. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
Kim E; Ahn H; Park H
Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
[TBL] [Abstract][Full Text] [Related]
11. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and immunotherapy of renal cell carcinoma.
Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
[TBL] [Abstract][Full Text] [Related]
14. The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?
Wieczorska K; Stolarek M; Stec R
Clin Colorectal Cancer; 2020 Mar; 19(1):5-12. PubMed ID: 31678050
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses.
Wong MK; Barbulescu P; Coburn B; Reguera-Nuñez E
Microbes Infect; 2021; 23(6-7):104804. PubMed ID: 33652120
[TBL] [Abstract][Full Text] [Related]
16. Microbiome bacterial influencers of host immunity and response to immunotherapy.
Yousefi Y; Baines KJ; Maleki Vareki S
Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
[TBL] [Abstract][Full Text] [Related]
17. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu X; Li S; Wang L; Ma K
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
[TBL] [Abstract][Full Text] [Related]
18. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
20. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
Zhao H; Wang D; Zhang Z; Xian J; Bai X
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
